OBJECTIVE: After menopause, women experience changes in body composition, especially an increase in fat mass. In addition, advancing age, decreased physical activity, and increased inflammation may predispose them to develop type 2 diabetes. Isoflavones have been shown to improve metabolic parameters in postmenopausal women. However, the effect of isoflavones on adipokines/cytokines remains unclear. The purpose of this study was to evaluate the effect of high-dose isoflavones on inflammatory and metabolic markers in postmenopausal women. METHODS: We measured glucose, insulin, and adipokines/cytokines in 75 healthy postmenopausal women who were randomized to receive 20 g of soy protein with 160 mg of total isoflavones (64 mg genistein, 63 mg daidzein, and 34 mg glycitein) or 20 g of soy protein placebo for 12 weeks. Women taking estrogen discontinued therapy at least 3 months before the study. The supplements were given in a powder form and consumed once daily with milk or other beverages. RESULTS: Mean ages in the placebo and active groups were similar (P = 0.4). Average time since menopause was 9 years, and two thirds of the women underwent natural menopause. There was no significant difference in body mass index at baseline between the groups (placebo, 25.1 kg/m; active, 26 kg/m) and it did not change significantly during the study. At baseline, the placebo group had significantly higher levels of tumor necrosis factor alpha (P < 0.0001); otherwise, there was no difference in any other parameter. After 12 weeks of treatment, there were significant positive changes in tumor necrosis factor alpha levels within the placebo group (P < 0.0001) and adiponectin levels within the isoflavone group (P = 0.03). Comparison of pre-post change between the groups showed a small but significant increase in serum adiponectin levels in the isoflavone group (P = 0.03) compared with the placebo group. No significant changes were seen in any other parameter between the two groups. CONCLUSIONS:Healthy, normal-weight postmenopausal women may not experience improvement in metabolic parameters when given high-dose isoflavones despite an increase in serum adiponectin levels. The role of isoflavones in obese and insulin-resistant postmenopausal women needs exploration.
RCT Entities:
OBJECTIVE: After menopause, women experience changes in body composition, especially an increase in fat mass. In addition, advancing age, decreased physical activity, and increased inflammation may predispose them to develop type 2 diabetes. Isoflavones have been shown to improve metabolic parameters in postmenopausal women. However, the effect of isoflavones on adipokines/cytokines remains unclear. The purpose of this study was to evaluate the effect of high-dose isoflavones on inflammatory and metabolic markers in postmenopausal women. METHODS: We measured glucose, insulin, and adipokines/cytokines in 75 healthy postmenopausal women who were randomized to receive 20 g of soy protein with 160 mg of total isoflavones (64 mg genistein, 63 mg daidzein, and 34 mg glycitein) or 20 g of soy protein placebo for 12 weeks. Women taking estrogen discontinued therapy at least 3 months before the study. The supplements were given in a powder form and consumed once daily with milk or other beverages. RESULTS: Mean ages in the placebo and active groups were similar (P = 0.4). Average time since menopause was 9 years, and two thirds of the women underwent natural menopause. There was no significant difference in body mass index at baseline between the groups (placebo, 25.1 kg/m; active, 26 kg/m) and it did not change significantly during the study. At baseline, the placebo group had significantly higher levels of tumor necrosis factor alpha (P < 0.0001); otherwise, there was no difference in any other parameter. After 12 weeks of treatment, there were significant positive changes in tumor necrosis factor alpha levels within the placebo group (P < 0.0001) and adiponectin levels within the isoflavone group (P = 0.03). Comparison of pre-post change between the groups showed a small but significant increase in serum adiponectin levels in the isoflavone group (P = 0.03) compared with the placebo group. No significant changes were seen in any other parameter between the two groups. CONCLUSIONS: Healthy, normal-weight postmenopausal women may not experience improvement in metabolic parameters when given high-dose isoflavones despite an increase in serum adiponectin levels. The role of isoflavones in obese and insulin-resistant postmenopausal women needs exploration.
Authors: M J de Kleijn; Y T van der Schouw; P W Wilson; H Adlercreutz; W Mazur; D E Grobbee; P F Jacques Journal: J Nutr Date: 2001-06 Impact factor: 4.798
Authors: Vijay Jayagopal; Paula Albertazzi; Eric S Kilpatrick; Elaine M Howarth; Paul E Jennings; David A Hepburn; Stephen L Atkin Journal: Diabetes Care Date: 2002-10 Impact factor: 19.112
Authors: Jacques E Rossouw; Garnet L Anderson; Ross L Prentice; Andrea Z LaCroix; Charles Kooperberg; Marcia L Stefanick; Rebecca D Jackson; Shirley A A Beresford; Barbara V Howard; Karen C Johnson; Jane Morley Kotchen; Judith Ockene Journal: JAMA Date: 2002-07-17 Impact factor: 56.272
Authors: Daniel R Christie; Jan Grant; Betty E Darnell; Victoria R Chapman; Amalia Gastaldelli; Cynthia K Sites Journal: Am J Obstet Gynecol Date: 2010-05-01 Impact factor: 8.661
Authors: Joshua K Napora; Ryan G Short; Denis C Muller; Olga D Carlson; Juliana O Odetunde; Xiaoqiang Xu; Michael Carducci; Thomas G Travison; Marcello Maggio; Josephine M Egan; Shehzad Basaria Journal: J Androl Date: 2010-08-26
Authors: Adana A Llanos; Juan Peng; Michael L Pennell; Jessica L Krok; Mara Z Vitolins; Cecilia R Degraffinreid; Electra D Paskett Journal: J Clin Endocrinol Metab Date: 2014-01-01 Impact factor: 5.958
Authors: C M Rebholz; K Reynolds; M R Wofford; J Chen; T N Kelly; H Mei; P K Whelton; J He Journal: Eur J Clin Nutr Date: 2012-11-28 Impact factor: 4.016
Authors: Marija Glisic; Natyra Kastrati; Valentina Gonzalez-Jaramillo; Wichor M Bramer; Fariba Ahmadizar; Rajiv Chowdhury; Ah Jan Danser; Anton Jm Roks; Trudy Voortman; Oscar H Franco; Taulant Muka Journal: Adv Nutr Date: 2018-11-01 Impact factor: 8.701
Authors: Javad Sharifi-Rad; Cristina Quispe; Muhammad Imran; Abdur Rauf; Muhammad Nadeem; Tanweer Aslam Gondal; Bashir Ahmad; Muhammad Atif; Mohammad S Mubarak; Oksana Sytar; Oxana Mihailovna Zhilina; Ekaterina Robertovna Garsiya; Antonella Smeriglio; Domenico Trombetta; Daniel Gabriel Pons; Miquel Martorell; Susana M Cardoso; Ahmad Faizal Abdull Razis; Usman Sunusi; Ramla Muhammad Kamal; Lia Sanda Rotariu; Monica Butnariu; Anca Oana Docea; Daniela Calina Journal: Oxid Med Cell Longev Date: 2021-07-19 Impact factor: 6.543